13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

HSCS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for HeartSciences Inc. (HSCS), a Healthcare sector company. HSCS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), HeartSciences Inc. reports net income of $-2.0M, free cash flow of $-1.5M. Top institutional holders of HSCS by reported 13-F value include DRW Securities,, TFB Advisors, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. HSCS trades on the Nasdaq exchange and files with the SEC under CIK 1468492. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HSCS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HeartSciences Inc. directly from SEC EDGAR.

Revenue

Q3 2026

$0.00

Net Income

Q3 2026

$-2.0M

Free Cash Flow

Q3 2026

$-1.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-76.6% YoY
$4.3KFY 2025
FY22 $14.4KFY23 $5.2KFY24 $18.6KFY25 $4.3K

Net Income

-32.7% YoY
$-8.8MFY 2025
FY22 $-4.8MFY23 $-6.4MFY24 $-6.6MFY25 $-8.8M

Operating Income

-32.5% YoY
$-8.4MFY 2025
FY22 $-4.7MFY23 $-6.1MFY24 $-6.3MFY25 $-8.4M

EPS (Diluted)

+50.2% YoY
$-4.67FY 2025
FY22 $-1.45FY23 $-80.00FY24 $-9.37FY25 $-4.67

Total Assets

-55.6% YoY
$4.2MFY 2025
FY22 $2.1MFY23 $3.3MFY24 $9.5MFY25 $4.2M

Op. Cash Flow

-22.1% YoY
$-7.4MFY 2025
FY22 $-3.6MFY23 $-5.8MFY24 $-6.1MFY25 $-7.4M

Get alerted when HSCS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HeartSciences Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put HSCS on your watchlist

Track score changes the day HeartSciences Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is HSCS a good stock to buy?

13F Pro's AI-powered analysis of HeartSciences Inc. (HSCS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HSCS are available on the HSCS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own HSCS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HSCS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HeartSciences Inc.'s investment landscape.